tbuckley/cabot-search huggingface dataset:
Noninvasive arterial thrombolysis with shock waves Giovanni Belcaro, Marco Bucci, Maria Rosaria Cesarone, Lucrezia Incandela, Mariateresa De Sanctis, Maura Griffin, Surinder Dhanjil, Michael Sabetai, George Geroulakos, Ernst Marlinghaus, Andrew N. Nicolaides. Biomedical Sciences Department Chieti University, Chieti, Italy, St Mary's Hospital &amp; Imperial College, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
ECLIPSE BLINDNESS
Authors: W. O. Lodge
Journal: BMJ (1921)

Vtia recent .;elipsearoused widespread interest, and was viewed -by all and sundry under exceptional'y favourable eirh-umstancces.Tllouglh the newspapers warned ltheir readers look at the slun only .througl a piece' of smoked& glass-or through an over-exposed photouraphlii plate, it- wx5 onlytv be expected that-a few peisons.shouLld suffer iijury to sight owing to neglect of adequate precautions of this.kind i.-I propose to describe two such cases.Since tlle con- dition is so -infrequent, it may not be out of place to mention tllat it differs from certain allied injuries 'in tli-tt it is complicated neither by concussion nor electrolytic effect.'Thle calinge is probably of a chemical nature b-rought about by too prolonged concentration of the ultra-violet, clhemical active rays it-t-he retinal elements at tihemacula.. Any-damage fron-i coplcentration of,the heat rays is probably prevented from a.redutio,u in their potency by passing throuah, the refra,ctive media."'The characteristic symptont is the presence of a central scotoma.When closely examined the clinical picture reveals a certain complexity of com- position.
Reperfusion imaging in anterior myocardial infarction. The open perforator hypothesis Paolo Voci, Enrica Mariano, Francesco Pizzuto, Francesco Monti, Gianluca Plaustro, Giovanni Testa, Mario Cardini, Paolo E. Puddu. Section of Cardiology II University of Rome ?La Sapienza?, Rome Italy, ?Celio? Military Hospital, Rome, Italy
Journal: Journal of the American College of Cardiology (2001)
A new look at an old operation: Evaluation and follow-up of patients with left ventricular apical to aortic conduits using two- and three-dimensional magnetic resonance imaging and doppler echocardiography Mark A. Fogel, Jack Rychik, Anne Hubbard, Alvin Chin, Paul M. Weinberg. The Children's Hospital of Philadelphia, Philadelphia, PA, University of Pennsylvania School of Medicine, Philadelphia, PA
Journal: Journal of the American College of Cardiology (2001)
Book Reviews
Authors: Matti Joukamaa, Hasse Karlsson, Britta Sohlman, Ville Lehtinen, Giovanni A. Fava, Fuad Lechin, Berta van der Dijs, Mireya Benaim, P. Bech, C. Gudex, K. Staehr Johansen, Frits J. Bekker, Uwe Hentschel, Michiko Fujita, Howard Berenbaum, Stacey Irvin, Per Høglend, Gail Q. Heather-Greener, Dana Comstock, Roby Joyce, Ernest H. Friedman
Journal: Psychotherapy and Psychosomatics (1996)
Genomic landscape of <i>ERBB2/3</i> alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype.
Authors: Jeanne Tie, Sherif Mohamed El-Refai, Takayuki Yoshino, Salvatore Siena, Sara Lonardi, Andrea Sartore-Bianchi, Yoshiaki Nakamura, Hideaki Bando, Takao Fujisawa, Sheau Wen Lok, Hui-Li Wong, Kunal C. Kadakia, Elizabeth Mauer, Mohamed E. Salem
Journal: Journal of Clinical Oncology (2022)

176 Background: ERBB2 is a rapidly emerging therapeutic target for a subset of colorectal cancer (CRC) harboring oncogenic alterations in this gene. Oncogenic ERBB3 mutations have been reported in various cancers including CRC, but little is known about its functional impact. Optimal targeting of this pathway requires understanding of the genomic context in which somatic ERBB2/3 alterations ( ERBB2/3-alt) occur in a real-world CRC population. Methods: We analyzed 7,688 de-identified records from CRC patients that underwent next generation sequencing with the Tempus|xT assay (DNA-seq of 648 genes at 500x coverage, full transcriptome RNA-seq). We assessed the prevalence and association of ERBB2/3-alt with demographics, co-occurring alterations, immuno-oncology biomarkers (microsatellite instability [MSI], tumor mutational burden [TMB], PD-L1 expression), and consensus molecular subtype (CMS, available for the subgroup with primary biopsies and RNA data [n = 2,686]). Results: Overall, 5% (376/7688) of tumors harbored an ERBB2 or ERBB3-alt. 1.9% (n = 143) ERBB2-amplified, 1.3% (n = 97) ERBB2-mutated, 0.9% (n = 72) ERBB3-mutated, &lt; 1% other combinations (excluded from analyses). There were no significant differences in baseline demographics (e.g., age of onset, race and gender) between groups. Patients with ERBB2/3-alt were more likely to be MSI-high and TMB-high (Table). There was a trend towards higher prevalence of positive PD-L1 in ERBB3-alt vs ERBB3-WT tumors. We observed significant differences in co-occurring alterations among ERBB2/3-alt and WT groups (Table). CMS classification did not identify significant differences by ERBB2-alt or ERBB3-alt; ERBB2-alt compared to WT (CMS1: 8.6% vs 13%; CMS2: 24% vs 26%; CMS3: 20% vs 17%; CMS4: 30% vs 34%; p = 0.12) and ERBB3-alt compared to WT (CMS1: 24% vs 13%; CMS2: 12% vs 26%; CMS3: 16% vs 17%; CMS4: 40% vs 34%; p = 0.3). Conclusions: ERBB2/3 mutated CRC are more frequently MSI-H, TMB-high and KRAS mutated than ERBB2/3-WT tumors. Correlation of ERBB2/3 alterations with other genomic alterations including BRAF, TP53, CDK12, PIK3CA, and TOP2A will help advance the clinical development of HER2-targeted therapies.[Table: see text]
LRP10 in α-synucleinopathies
Authors: Lasse Pihlstrøm, Lucia Schottlaender, Viorica Chelban, Henry Houlden, Safa Al-Sarraj, Thomas Arzberger, Conceicao Bettencourt, Kailash Bhatia, Dennis W Dickson, Monica Federoff, Ellen Gelpi, Steve Gentleman, John Hardy, Janice Holton, Inge Huitinga, Allan Levey, David Mann, Wassilios Meissner, Huw Morris, Chris Morris, Alan Pittman, Olivier Rascol, Peter Riederer, Ekaterina Rogaeva, Owen Ross, Sonja Scholtz, Andrew B Singleton, John Trojanowski, Jana Vandrovcova, Tom Warner, Nick Wood
Journal: The Lancet Neurology (2018)
Abstract 475: Human Saphenous Vein Progenitor Cells Are Susceptible to Mechanical Stimulation. Novel Insights in Pathologic Programming of Saphenous Vein Bypass Graft Disease
Authors: Gloria Garoffolo, Rosa Vono, Matteo Carrara, Rosaria Santoro, Stefano Zoli, Claudio Saccu, Fabio Martelli, Gaia Spinetti, Paolo Madeddu, Maurizio Pesce
Journal: Circulation Research (2017)

Background: Implantation of saphenous vein (SV) grafts into coronary position determines structural vessel wall remodeling and intimal hyperplasia. The role of the altered wall mechanics and cell-based mechanosensing has been recently implicated in the priming of this pathologic process. We investigated the effects of cyclic uniaxial strain on human saphenous vein progenitor cells (SVPs), a cell type endowed with pericyte stem cell characteristics resident in the adventitia. Methods: CD34 + CD31 - SVPs were isolated with immuno-magnetic sorting (MACS) from SVs of patients (age 58±12.6, Mean±SD) undergoing saphenectomy. Cells were subject to uniaxial strain (10% elongation; 1Hz) for 24 and 72 hrs using the FlexCell system. Cell orientation, immunofluorescence and western analyses were performed to assess the effects of strain on cell orientation/shape, cell cycle and activity of the YAP/Hippo-dependent mechanotransduction machinery. RNA-sequencing from control vs. strained SVPs was performed at both time points using RNA from cells of 5 independent donors. Results: Results indicated an increase in the expression of the cell cycle-associated markers Ki67 and pHH3 in mechanically stimulated vs. control SVPs at 24 hrs, followed by a significant reduction at 72 hrs of stimulation. Variations in cell shape was observed as verified by a significant change in the nuclei orientation in the strain field as well as in the cell shape index/spread areas at both time points. Immunofluorescence revealed a significant increase in cells showing a nuclear localization of the YAP transcription factor at 72hrs. In line with these findings Western analyses indicated a significant decrease in the ratio between phosphorylated/total YAP and its upstream kinase LATS in mechanically stimulated vs. control SVPs, suggesting an inhibition of the HIPPO kinase pathway by mechanosensing. RNASeq gene expression analyses showed a coherent modification of gene expression pathways and the upregulation of a specific HIPPO/YAP/TEAD gene expression signature in SVPs mechanically stimulated for 72hrs. Conclusions: These findings demonstrate the direct susceptibility of human SVPs to pathologic strain and identifies this cell population as mechano-perceptors in the vein wall.
Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.
Authors: Choong-kun Lee, Jingmin Che, Woo Sun Kwon, Sejung Park, Hyo Song Kim, Minkyu Jung, Hyun Cheol Cheol Chung, Sun Young Rha
Journal: Journal of Clinical Oncology (2022)

351 Background: Targeted panel next-generation sequencing (NGS) is now actively performed in clinics to guide treatment decisions for advanced cancer patients. However, NGS profilings of advanced gastric cancer (AGC) do not provide relevant genomic biomarkers that could predict response to second-line treatment for AGC patients yet. Methods: Two paclitaxel-based phase Ib/II trials as a second-line treatment for AGC patients were included: GSK2636771 (PI3Kβ selective inhibitor) and paclitaxel for AGC patients with PI3K/Akt pathway alterations (PTEN trial, NCT02615730, presented at GI ESMO 2021) and nivolumab and paclitaxel for EBV-related, dMMR/MSI-H or PD-L1 positive AGC (K-umbrella-003 trial, NCT02951091, presented at AACR 2021). Pre-treatment tumor tissue samples from two trials were subjected to the in-house panel sequencing using CancerMaster Panel V2 (Kwon et al., GI ASCO 2021) that covers 524 genes for single nucleotide variants, 143 for copy-number variations, and 18 for fusions. Baseline genomic alterations were compared with each patient’s response and survival. Oncogenic signaling pathways were annotated manually according to previous reports. Tumor mutation burden (TMB) and Human leukocyte antigen (HLA) profilings were also performed. Results: Baseline tumor tissues from 54 patients (24 from PTEN trial, 30 from K-umbrella-003 trial) were available for NGS. In patients treated with GSK2636771 and paclitaxel, patients with PIK3R1 M326I mutation (n = 3) showed longer PFS (8.1 vs 2.8 months, P= 0.041), and patients without MYC Q48H (n = 13) showed better PFS (4.8 vs 2.6 months, P= 0.013). Genetic alterations in epigenetic pathway were found in 13 patients (54.2%) and showed worse PFS (2.8 vs 5.0 months, P = 0.04). In patients treated with nivolumab and paclitaxel, patients with RTK/RAS pathway alterations excluding deletions (n = 21, 70%) showed significantly longer PFS (4.1 vs 2.6 months, P = 0.0085), and patients with HLA-A02 supertype (n = 11, 36.7%) showed significantly longer PFS (12.4 vs. 2.7 months, P = 0.0068). In both studies, TMB-high was not related to the survival and there were no common predictive genomic alterations. Conclusions: We observed that specific NGS-based genomic alterations such as single gene mutations, altered signaling pathways and HLA genotyping were potential predictors of each targeted agent or immunotherapy as a 2nd line treatment of AGC patients, regardless of paclitaxel. Further correlative studies within AGC trials for exploring predictive biomarkers are warranted. Clinical trial information: NCT02615730; NCT02951091.
Survival of patients waiting for heart transplant: The information brought by usual statistical techniques may be misleading Christine Mestre, Francois Delahaye, Guy de Gevigney, Muriel Rabilloud, Rene Ecochard, Corinne Ducreux, Georges Dureau, Hugues Milon. HOPITAL CARDIOLOGIQUE, LYON, France
Journal: Journal of the American College of Cardiology (2001)
Para athletes’ perceptions of abuse: a qualitative study across three lower resourced countries
Authors: Emily Anne Rutland, Sakinah C Suttiratana, Sheila da Silva Vieira, Rekha Janarthanan, Michael Amick, Yetsa A Tuakli-Wosornu
Journal: British Journal of Sports Medicine (2022)

Interpersonal violence is an increasingly recognised risk of sport participation and causally linked to negative physical and mental health outcomes. Para athletes from low- and middle-income countries may be at highest risk of physical, psychological, sexual and neglect-related violence due to various factors; however, their perceptions of these abusive behaviours are unknown. This study examined the perceptions and experiences of abuse in para athletes from three lower resourced countries: Ghana, India and Brazil.Qualitative data from semistructured focus group interviews conducted with 26 individuals were collected to explore characteristics of abuse observed, navigated and experienced by para athletes. The framework method for multidisciplinary qualitative research guided data analysis.Athletes identified a wide range of abusive behaviours they experienced within and outside of sport, including psychological, emotional, physical, sexual and neglect-related violence, which operated on both interpersonal and systemic levels. Most athletes described three less easily recognised forms of abuse in greater detail and more frequently than others: financial abuse, neglect and disability stigma.It is important to hear directly from athletes with diverse experiences and backgrounds and to integrate their insights and priorities into sport safeguarding policies, programmes and interventions. Understanding the requirements and challenges of para athletes and para sport is needed to achieve safe, equitable and inclusive sport. As new insights from diverse sport settings are added to the evidence base, globally balanced, athlete-generated and locally relevant preventative strategies can better protect all athletes.
Inhibition of intracellular proton-sensitive Ca2+-permeable TRPV3 channels protects against ischemic brain injury
Authors: Xiaoling Chen, Jingliang Zhang, KeWei Wang
Journal: Acta Pharmaceutica Sinica B (2022)

Ischemic brain stroke is pathologically characterized by tissue acidosis, sustained calcium entry and progressive cell death. Previous studies focusing on antagonizing N-methyl-d-aspartate (NMDA) receptors have failed to translate any clinical benefits, suggesting a non-NMDA mechanism involved in the sustained injury after stroke. Here, we report that inhibition of intracellular proton-sensitive Ca2+-permeable transient receptor potential vanilloid 3 (TRPV3) channel protects against cerebral ischemia/reperfusion (I/R) injury. TRPV3 expression is upregulated in mice subjected to cerebral I/R injury. Silencing of TRPV3 reduces intrinsic neuronal excitability, excitatory synaptic transmissions, and also attenuates cerebral I/R injury in mouse model of transient middle cerebral artery occlusion (tMCAO). Conversely, overexpressing or re-expressing TRPV3 increases neuronal excitability, excitatory synaptic transmissions and aggravates cerebral I/R injury. Furthermore, specific inhibition of TRPV3 by natural forsythoside B decreases neural excitability and attenuates cerebral I/R injury. Taken together, our findings for the first time reveal a causative role of neuronal TRPV3 channel in progressive cell death after stroke, and blocking overactive TRPV3 channel may provide therapeutic potential for ischemic brain injury.
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Lancet Healthy Longevity: Health For All, For Longer
Authors: None The Lancet Healthy Longevity
Journal: The Lancet Healthy Longevity (2020)

The coronavirus disease 2019 (COVID-19) pandemic does not affect everyone equally. While anyone can contract COVID-19, accumulating data suggest that older people or those with pre-existing comorbidities are far more likely to have severe complications or die from the disease. While researchers scramble to unravel the mechanisms of action underlying the disease's wide-ranging effects, news that the disease hits older people hardest has been received without demur: it is widely accepted that to be old is to be fragile.
Impact of stenting compared to balloon angioplasty on in-hospital outcomes of 44000 patients. Results from the registry of the Brazilian Society of Interventional Cardiology (CENIC) Marco A. Costa, Amanda G. M. R. Sousa, Luiz A. P. Mattos, Jamil Saad, Andre Labrunie, Fausto Feres, Alexandre Abizaid, Carlos Gottchall, Costantino Costantini, H�lio Figueira, Valter Lima, Paulo Caramori, Paulo Sergio Oliveira, Jos� Armando Mangione, J. Eduardo M. R. Sousa. Brazilian Society of Interventional …
Journal: Journal of the American College of Cardiology (2001)
Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning
Authors: L. M. Morsink, J. van Doesum, G. Choi, C. L. E. Hazenberg, A. Biswana, F. Meppelink, L. B. Bungener, A. J. A. Lambeck, G. Huls
Journal: Blood Cancer Journal (2022)
Wording Clarification in: Carpal Tunnel Syndrome
Authors: Marla Reicks, Joseph Redden, Traci Mann, Elton Mykerezi, Zata Vickers
Journal: JAMA (2012)

mean of 27.1 g; t 313 =5.28, PϽ.001), and the intervention was associated with a significant increase in the carrot consumption overall per exposed student (from mean of 3.6 g to 10.0 g; t 1311 =87.18,PϽ.001).Comment.Placing photographs in cafeteria lunch trays requires no special training and incurs minimal costs and labor (in this study, about $3 and 20 minutes per 100 trays), but was associated with an increase in vegetable consumption within the range of those found in more expensive interventions, including those that require multiple classroom sessions with trained instructors or parent involvement. 5The number of students taking vegetables and the amounts consumed, however, remained low and did not yet meet government recommendations.In addition, these findings were obtained from just 2 days in 1 school, so further research is needed to assess how well the effects generalize to other settings and persist over time.
Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis
Authors: Melanie C. Dispenza, Rebecca A. Krier-Burris, Krishan D. Chhiba, Bradley J. Undem, Piper A. Robida, Bruce S. Bochner
Journal: Journal of Clinical Investigation (2020)

No known therapies can prevent anaphylaxis. Bruton's tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells. We tested the hypothesis that FDA-approved BTK inhibitors (BTKis) would prevent IgE-mediated responses including anaphylaxis. We showed that irreversible BTKis broadly prevented IgE-mediated degranulation and cytokine production in primary human mast cells and blocked allergen-induced contraction of isolated human bronchi. To address their efficacy in vivo, we created and used what we believe to be a novel humanized mouse model of anaphylaxis that does not require marrow ablation or human tissue implantation. After a single intravenous injection of human CD34+ cells, NSG-SGM3 mice supported the population of mature human tissue-resident mast cells and basophils. These mice showed excellent responses during passive systemic anaphylaxis using human IgE to selectively evoke human mast cell and basophil activation, and response severity was controllable by alteration of the amount of allergen used for challenge. Remarkably, pretreatment with just 2 oral doses of the BTKi acalabrutinib completely prevented moderate IgE-mediated anaphylaxis in these mice and also significantly protected against death during severe anaphylaxis. Our data suggest that BTKis may be able to prevent anaphylaxis in humans by inhibiting FcεRI-mediated signaling.
Allied health education
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal